The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
 
Sacha Rothschild
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Roche Pharma AG
 
Alfred Zippelius
No Relationships to Disclose
 
Spasenija Savic
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - MSD; Roche
 
Michel Gonzalez
No Relationships to Disclose
 
Walter Weder
No Relationships to Disclose
 
Alexandros Xyrafas
No Relationships to Disclose
 
Corinne Rusterholz
No Relationships to Disclose
 
Miklos Pless
No Relationships to Disclose